Answers are grounded in this paper and cite their sources.
Retrospective study shows viral triggers and presentation of bronchiolitis obliterans in pediatric cases, indicating younger age correlates with increased disease severity.
A study of French children by Mazenq et al., published in Acta Paediatrica, concluded that younger age and viral triggers were associated with post-infectious bronchiolitis obliterans (PIBO) [1]. The authors' retrospective study of 147 children with PIBO was diagnosed and managed in French RespiRare reference centers. This paper provides the first European epidemiological description of this rare condition and provides novel insights into the factors associated with the course of the disease. Bronchiolitis obliterans is an infrequent complication of a severe insult to the lowest peripheral airways [2]. Three categories have been identified in children, and the most common one is PIBO, which is seen in most paediatric respiratory units. The other two are less familiar to paediatricians, as they only tend to be seen in specialist centres. These are when bronchiolitis obliterans occurs after a haematopoietic stem cell transplant or manifests as a lung transplant complication [2]. The histology of these entities is somewhat similar, despite different triggers. Bronchiolitis obliterans is characterised by inflammation and fibrosis in the terminal and respiratory bronchioles, with distorted airway wall architecture, lumen narrowing and sometimes complete obliteration [3]. Post-infectious bronchiolitis obliterans has been documented after several common viruses, such as adenoviruses, the respiratory syncytial virus, influenza, measles and varicella. It has also been seen after mycoplasma pneumoniae infection. All of these microbes can cause a broad spectrum of acute bronchiolitis and pneumonia that normally resolves completely. Histopathological findings in patients with bronchiolitis obliterans suggest that the initial injury to the airway epithelium results in an abnormal host repair response, rather than normal epithelial regeneration [3]. The exact pathophysiological mechanisms of this are unknown, but data from some lung biopsies have suggested that prolonged lymphocytic inflammation continues in the peribronchiolar tissue after the acute hit. This could indicate an immunological basis [4]. Lack of knowledge about the pathogenesis of PIBO has hindered the development of effective therapies [5]. Some indirect evidence on anti-inflammatory treatment with fluticasone, azithromycin and montelukast has appeared in studies on bronchiolitis obliterans after haematopoietic stem cell transplants [6] and lung transplants [7, 8]. However, no controlled studies on PIBO have been published. So far, only high-dose pulse steroid therapy has shown any benefit in these patients, and it is also believed to be more effective when delivered early in the disease course [9]. Steroids combined with azithromycin had some effect in a retrospective PIBO series [10]. Likewise, a course of systemic steroid pulses, combined with oral azithromycin, is usually prescribed for three to 6 months for PIBO. However, no controlled studies have been carried out; empirical treatment has mainly been based on expert consensus [5]. Mazenq et al. retrospectively collected data on PIBO from 18 centres belonging to the RespiRare network. The diagnoses were reviewed to exclude other conditions, such as ciliary dyskinesia or cystic fibrosis, and, most importantly, after haematopoietic stem cell transplants or solid organ transplants. There were 147 children diagnosed with PIBO during 2017–2023, which was a very low annual prevalence in a population of approximately 12 million French children. The study also represents periods before, during, and after the pandemic and reveals trends in annual prevalence in line with social restrictions due to the emergence of COVID-19. In most cases, the inclusions and diagnoses were made after computed tomography imaging revealing mosaic pattern attenuation that was associated with persistent respiratory symptoms. An irreversible obstructive lung function profile, which is a characteristic finding in PIBO, was seen in 17 (50.0%) of the 34 children who underwent lung function testing. Most of the cohort were too young for such tests. Bronchoscopy was carried out on 66.9% of the patients at the time of diagnosis, but surgical lung biopsies were only taken in one case. This highlights the fact that computed tomography is the primary diagnostic tool for PIBO. A bronchoscopy with lavage is often needed to exclude infections when PIBO is suspected, but an invasive lung biopsy may not be warranted to exclude other conditions. As the children may be severely ill, carrying out an open lung biopsy early in the disease course may lead to clinical deterioration. The median age at the time of the PIBO diagnoses was only 22 months, but there was a broad age range, from 1 month to 16 years. More than half (58.5%) of the children were less than 2 years old; 27.2% were between 2 and 6 years and 14.3% were older than that. Most of the children (83.7%) had been admitted due to the initial infection and 36.7% were treated in intensive care units, reflecting the fact that PIBO often follows severe respiratory difficulties. A novel insight of the study was that younger age groups were admitted to acute care wards and intensive care units more often than older children and had a more severe initial disease course. On the other hand, some cases must have been significantly milder, as no initial admissions were reported in 16.3% of the cases. Mazenq et al. documented a range of different predisposing pathogens and a high prevalence of adenoviruses in the youngest age group, which was also linked to more severe initial respiratory events. These had been reported by other studies. However, the respiratory syncytial virus was found almost as often as adenoviruses in children under 2 years of age and was presumed to be an aetiological agent. This suggests that there could be a window of opportunity to prevent some of these cases with novel, effective RSV antibodies and maternal vaccination programmes. In this cohort, PIBO was mainly associated with mycoplasma pneumoniae in school-aged children, even though other studies have described it as the second most common predisposing pathogen, even in small children [10]. Empirical treatment primarily involved inhaled corticosteroids in 90.7% of cases, azithromycin in 59.2% and oral corticosteroids in 12.2%. Pulse intravenous corticosteroids were administered in 40.8% of severe cases. Prolonged need for respiratory support or oxygen after the initial hospital stay was reported in 18.4% of cases, lasting an average of 3.4 months. The longest duration was 17 months. The fact that there were variations in the chosen treatments probably reflected the diverse disease presentation in this cohort. The long-term prognosis of PIBO was documented only in minor detail in the paper [1]. It had previously been suggested that the initial treatment of the predisposing infection and the following host response played important roles [2]. However, PIBO can be a devastating and chronic disease in many cases, as it often affects otherwise healthy children. They may remain clinically stable but have impaired pulmonary function, which may only partially improve with growth. Although mortality due to PIBO is rare, it can happen because of pulmonary complications, as presented in one case in the current study [1]. Another study reported that PIBO can lead to end-stage lung disease and lung transplants at a young age [11]. To conclude, the paper by Mazenq et al. describes what they believe to be the first European cohort of children diagnosed with PIBO. The authors used retrospective data to summarise the clinical characteristics of children aged 1 month to 16 years and the treatment they received. The findings suggest significant variations in presentation and aetiological pathogens and link younger age and adenoviruses to more difficult disease courses. It is clear that more accurate data is needed on the pathophysiological mechanisms that lead to PIBO if novel effective treatments are to be developed. But we need more information on the basic numbers, such as disease prevalence and the available treatment options to start planning controlled studies. That is why the data from the Manzenq et al. study is most welcome. The author declares no conflicts of interest. The author has nothing to report.
No takes yet. Share an insight, caveat, or question.
Eero Lauhkonen (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: